RevenanasBook a free audit

M&A

Lonza agrees to buy 5 Merck KGaA US manufacturing facilities for ADC and viral vector production

November 3, 2026

Biotech

M&A

Key Facts

Signal Type

M&A

Industry

Biotech

Companies

Lonza, Merck KGaA, William Blair, Roche, Samsung Biologics

Date

November 3, 2026

What Happened

Lonza has agreed to buy five Merck KGaA US manufacturing facilities in a deal valued at approximately CHF 350 million. The sites cover bioconjugation (St. Louis, MO), high-potency payload-linkers (Madison and Verona, WI), viral vectors (Carlsbad, CA), and aseptic fill-finish (Indianapolis, IN).

About 1,100 employees will transfer to Lonza as part of the acquisition. Lonza expects the deal to close in mid-2027 and projects the acquired facilities to contribute roughly CHF 250 million in sales by 2028.

Who Is Affected

The acquisition directly impacts the ~1,100 transferring employees, who will need to be integrated into Lonza's systems and culture. It also affects current and prospective customers of these five plants, as Lonza plans to broaden the customer pipeline and increase capacity utilization.

Lonza's existing US operations — now expanding to nine sites with over 6,000 employees — will see changes in how ADC and viral vector services are delivered across both US and European (Visp, Switzerland) locations.

Market Impact

Lonza strengthens its position in high-growth modalities, particularly ADCs and viral vectors, at a time when the global bioconjugation market is projected to grow from $30 billion to $110 billion by 2033.

  • Adds US-based end-to-end ADC drug substance manufacturing, enabling earlier customer engagement and dual-continent supply.
  • Addresses underutilized capacity at the acquired plants, creating potential for significant sales growth.
  • Signals continued M&A appetite from Lonza, with the CEO stating the company will not hesitate to pursue further deals in parallel.

What to Watch

Watch for integration milestones between now and mid-2027, including IT, HR, and operational systems consolidation across the five sites. Also monitor how quickly Lonza can raise capacity utilization and bring margins in line with its existing business by the mid-2030s.

Industry watchers should also track whether Lonza announces additional acquisitions while integrating these plants, as the CEO explicitly signaled readiness for parallel deal-making.

Related coverage

Source:

BioSpace

Get biotech signals in your CRM

FDA approvals and rejections, clinical trial results, pharma M&A, drug recalls, and funding rounds.

Book a 15 min call
Dominykas Rukas - Revenanas

More from this industry

    We can send changes like these to your own CRM, matched to the accounts your team sells to.

    Book a free audit

    Built in your tools.
    Run by your team.

    Tell us the commercial goal and where it gets stuck. We find the bottleneck with you and plan the first two week sprint from it.

    Dominykas Rukas, RevenanasDominykas RukasCo-founderBook a free audit
    • HubSpot partner badgeHubSpot partner
    • Enterprise Clay partner